AstraZeneca, Lilly collaborate to test new cancer drug combination
AstraZeneca and Eli Lilly deepening their collaboration in cancer immunotherapy by testing new drug combinations for treating solid tumours.
[adsense:336x280:8701650588]
Lilly will lead the studies, while both companies will contribute resources. Details of financial arrangements and tumours to be studied were not disclosed.
AstraZeneca's anti-PD-L1 medicine durvalumab would be combined with Lilly molecules, including a TGF-beta kinase inhibitor, a CXCR4 peptide antagonist and an anti-CSF-1R monoclonal antibody, which will also be assessed with AstraZeneca's tremelimumab.
[adsense:468x15:2204050025]
They will also explore other combinations targeting tumour drivers and resistance mechanisms.
Subscribe to PharmaTutor News Alerts by Email >>